ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
ZymoGenetics has signed a licensing agreement under which Novo Nordisk will gain worldwide rights to IL-21 mAb, a fully human monoclonal antibody being developed as a treatment for autoimmune and inflammatory diseases. Novo, which has had intellectual property rights to IL-21 mAb outside North America since 2001, will pay ZymoGenetics $24 million up front. Additional milestone payments could reach $157.5 million. Separately, ZymoGenetics will eliminate 52 jobs, a 15% workforce reduction, in an effort to cut costs by focusing on projects furthest along in development.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X